Samantha Cooper

Dr. Samantha Cooper

University of Nottingham
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCSamantha Cooper
Samantha Cooper
EBEleanor Boyle
Eleanor Boyle
SJSophie Jefferson
Sophie Jefferson
CHCalum Heslop
Calum Heslop
PMPirathini Mohan
Pirathini Mohan
Jeanette WoolardJeanette Woolard
Jeanette Woolard
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. Patients may present as asymptomatic or demonstrate mild to severe and life-threatening symptoms. Although COVID-19 has a respiratory focus, there are major cardiovascular complications (CVCs) associated with infection. The reported CVCs include myocarditis, heart failure, arrhythmias, thromboembolism and blood pressure abnormalities. These occur, in part, because of dysregulation of the Renin–Angiotensin–Aldosterone System (RAAS) and Kinin–Kallikrein System (KKS). A major route by which SARS-CoV-2 gains cellular entry is via the docking of the viral spike (S) protein to the membrane-bound angiotensin converting enzyme 2 (ACE2). The roles of ACE2 within the cardiovascular and immune systems are vital to ensure homeostasis. The key routes for the development of CVCs and the recently described long COVID have been hypothesised as the direct consequences of the viral S protein/ACE2 axis, downregulation of ACE2 and the resulting damage inflicted by the immune response. Here, we review the impact of COVID-19 on the cardiovascular system, the mechanisms by which dysregulation of the RAAS and KKS can occur following virus infection and the future implications for pharmacological therapies.

1 November 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HSHardip Sandhu
Hardip Sandhu
SCSamantha Cooper
Samantha Cooper
AHAfthab Hussain
Afthab Hussain
CMChristopher Mee
Christopher Mee
HMHelen Maddock
Helen Maddock

14 January 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SCSamantha Cooper
Samantha Cooper
MSMark Soave
Mark Soave
MJManuela Jörg
Manuela Jörg
PSPeter J. Scammells
Peter J. Scammells
Jeanette WoolardJeanette Woolard
Jeanette Woolard
SHStephen Hill
Stephen Hill
Background and Purpose Adenosine is a local mediator that regulates a number of physiological and pathological processes via activation of adenosine A1‐receptors. The activity of adenosine can be regulated at the level of its target receptor via drugs that bind to an allosteric site on the A1‐receptor. Here, we have investigated the species and probe dependence of two allosteric modulators on the binding characteristics of fluorescent and nonfluorescent A1‐receptor agonists. Experimental Approach A Nano‐luciferase (Nluc) BRET (NanoBRET) methodology was used. This used N‐terminal Nluc‐tagged A1‐receptors expressed in HEK293T cells in conjunction with both fluorescent A1‐receptor agonists (adenosine and NECA analogues) and a fluorescent antagonist CA200645. Key Results PD 81,723 and VCP171 elicited positive allosteric effects on the binding affinity of orthosteric agonists at both the rat and human A1‐receptors that showed clear probe dependence. Thus, the allosteric effect on the highly selective partial agonist capadenoson was much less marked than for the full agonists NECA, adenosine, and CCPA in both species. VCP171 and, to a lesser extent, PD 81,723, also increased the specific binding of three fluorescent A1‐receptor agonists in a species‐dependent manner that involved increases in Bmax and pKD. Conclusions and Implications These results demonstrate the power of the NanoBRET ligand‐binding approach to study the effect of allosteric ligands on the binding of fluorescent agonists to the adenosine A1‐receptor in intact living cells. Furthermore, our studies suggest that VCP171 and PD 81,723 may switch a proportion of A1‐receptors to an active agonist conformation (R*).

Verified
Journal Article
Open access
PDF file
PPPatrizia Pannucci
Patrizia Pannucci
SJSophie Jefferson
Sophie Jefferson
JHJonathan Hampshire
Jonathan Hampshire
SCSamantha Cooper
Samantha Cooper
SHStephen Hill
Stephen Hill
Jeanette WoolardJeanette Woolard
Jeanette Woolard
The clinical manifestations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection responsible for coronavirus disease 2019 (COVID-19) commonly include dyspnoea and fatigue, and they primarily involve the lungs. However, extra-pulmonary organ dysfunctions, particularly affecting the cardiovascular system, have also been observed following COVID-19 infection. In this context, several cardiac complications have been reported, including hypertension, thromboembolism, arrythmia and heart failure, with myocardial injury and myocarditis being the most frequent. These secondary myocardial inflammatory responses appear to be associated with a poorer disease course and increased mortality in patients with severe COVID-19. In addition, numerous episodes of myocarditis have been reported as a complication of COVID-19 mRNA vaccinations, especially in young adult males. Changes in the cell surface expression of angiotensin-converting enzyme 2 (ACE2) and direct injury to cardiomyocytes resulting from exaggerated immune responses to COVID-19 are just some of the mechanisms that may explain the pathogenesis of COVID-19-induced myocarditis. Here, we review the pathophysiological mechanisms underlying myocarditis associated with COVID-19 infection, with a particular focus on the involvement of ACE2 and Toll-like receptors (TLRs).

1 February 2018 in Toxicology
Verified
Journal Article
Closed access
SCSamantha Cooper
Samantha Cooper
HSHardip Sandhu
Hardip Sandhu
AHAfthab Hussain
Afthab Hussain
CMChristopher Mee
Christopher Mee
HMHelen Maddock
Helen Maddock